Credit: ViiV Healthcare. The new blister pack is a monthly 30-count box containing 5 sheets of tablets; each sheet is perforated and is about "the size of a credit card" offering more discreet ...
Findings showed 26 of the 30 participants achieved and maintained viral suppression (HIV-1 RNA 50c/mL) at week 48. The Food and Drug Administration (FDA) has expanded ...
In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) ...
The MarketWatch News Department was not involved in the creation of this content. -- Dovato is now the first and only oral, two-drug, single-tablet regimen available for people aged 12 and older ...
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato ...
(Reuters) - GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a ...
Shionogi now plans to accelerate its expansion in Europe and the U.S., while pursuing full-scale growth of its new drug business in China. New growth areas include sleep apnea, pompe disease, hearing ...
Ann Edwards looks exactly like what she is—a loving wife, mother and grandmother—a retired school administrator living in Connecticut. She is also an HIV patient taking GSK ViiV’s Dovato. If this ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 96-week findings from PASO DOBLE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback